Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.

    Pediatrics 2017 Jul;140(Suppl 1):S24-S45
    Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina
    After a Pompe disease diagnosis is confirmed in infants identified through newborn screening (NBS), when and if to start treatment with enzyme replacement therapy (ERT) with alglucosidase alfa must be determined. In classic infantile-onset Pompe disease, ERT should start as soon as possible. Once started, regular, routine follow-up is necessary to monitor for treatment effects, disease progression, and adverse effects. Decision-making for when or if to start ERT in late-onset Pompe disease (LOPD) is more challenging because patients typically have no measurable signs or symptoms or predictable time of symptom onset at NBS. With LOPD, adequate, ongoing follow-up and assessments for onset or progression of signs and symptoms are important to track disease state and monitor and adjust care before and after treatment is started. Because numerous tests are used to monitor patients at variable frequencies, a standardized approach across centers is lacking. Significant variability in patient assessments may result in missed opportunities for early intervention. Management of Pompe disease requires a comprehensive, multidisciplinary approach with timely disease-specific interventions that target the underlying disease process and symptom-specific manifestations. Regardless of how identified, all patients who have signs or symptoms of the disease require coordinated medical care and follow-up tailored to individual needs throughout their lives. The Pompe Disease Newborn Screening Working Group identifies key considerations before starting and during ERT; summarizes what comprises an indication to start ERT; and provides guidance on how to determine appropriate patient management and monitoring and guide the frequency and type of follow-up assessments for all patients identified through NBS.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
    Source Status
    http://dx.doi.org/10.1542/peds.2016-0280EDOI ListingPossible

    Similar Publications

    Pompe disease: early diagnosis and early treatment make a difference.
    Pediatr Neonatol 2013 Aug 28;54(4):219-27. Epub 2013 Apr 28.
    Department of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
    Pompe disease (glycogen storage disease type II or acid maltase deficiency) is a lysosomal disorder in which acid α-glucosidase (GAA) deficiencies lead to intralysosomal accumulation of glycogen in all tissues; most notably in skeletal muscles. Both the patient's age at the onset of Pompe disease symptoms and the rate of deterioration caused by the disease can vary considerably. In classical infant-onset Pompe disease (IOPD), symptoms start very early in life, and death occurs soon afterward if the disease remains untreated. Read More
    The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Am J Med Genet C Semin Med Genet 2012 Feb 17;160C(1):1-7. Epub 2012 Jan 17.
    DUMC, Durham, NC 27710, USA.
    Pompe disease is an autosomal recessive neuromuscular disorder marked by progressive muscle weakness due to lysosomal buildup of glycogen. Presentation is described as a spectrum, varying by age of onset, organ involvement, and degree of myopathy. Given the phenotypic variability, Pompe disease is broadly classified into an infantile form and a late onset (juvenile, childhood, adult onset) form. Read More
    Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
    J Neurol 2013 Apr 28;260(4):951-9. Epub 2012 Aug 28.
    Department of Neurosciences, Psychiatry and Anesthesiology, AOU Policlinico "G. Martino", University of Messina, 98125 Messina, Italy.
    Glycogen storage disease type 2/Pompe disease is a progressive muscle disorder with a wide range of phenotypic presentations, caused by an inherited deficiency of acid alpha-glucosidase. Since 2004 only a limited number of patients have been treated with recombinant human alpha-glucosidase from rabbit milk whereas since 2006 enzyme replacement therapy (ERT) with alglucosidase alfa has been licensed for the treatment of Pompe disease. This systematic review evaluates the clinical efficacy and safety of alglucosidase alfa treatment of juvenile and adult patients with late-onset Pompe disease (LOPD). Read More
    Newborn screening for Pompe disease: an update, 2011.
    Am J Med Genet C Semin Med Genet 2012 Feb 17;160C(1):8-12. Epub 2012 Jan 17.
    Division of Genetics, Birth Defects and Metabolism, Children's Memorial Hospital, Chicago, IL 60614, USA.
    There is mounting evidence in support of universal newborn screening for Pompe disease. Early treatment of children with infantile Pompe disease, prior to clinical diagnosis, is clearly of benefit in prolonging survival and improving cardiac and motor function. Several testing methods applicable to newborn screening using dried blood spots have been described and several are currently being tested in pilot screening programs. Read More